Jazz's record $1.2B quarter masks a $754M Actio charge as Ziihera launch begins

The quarter in numbers

Jazz Pharmaceuticals reported third-quarter 2026 total revenues of $1,243.0 million, up 10% from $1,126.1 million a year earlier, which the company called a record. Nine-month revenues reached $3,520.2 million against $3,069.6 million.

The bottom line was driven by one item. Jazz booked a GAAP net loss of $483.4 million, or $(7.48) per share, versus net income of $251.4 million ($4.08) in 3Q25. Non-GAAP adjusted net loss was $250.8 million, or $(3.88) per share, versus adjusted net income of $500.7 million ($8.13). The company attributed the swing to $754 million of acquired in-process R&D, the value allocated to ABS-1230 (JZP6979) in the Actio acquisition. That charge cost $11.32 per share on a GAAP basis and $11.03 on a non-GAAP adjusted basis.

What drove revenue

Sleep remained the largest franchise at $514.0 million, up from $467.1 million. Xywav net sales rose 12% to $482.8 million. The company said it added about 425 net patients in the quarter and exited with about 17,550 active patients: about 11,375 in narcolepsy and about 6,175 in idiopathic hypersomnia. Xyrem slipped to $31.2 million from $35.7 million, and high-sodium oxybate authorized-generic royalty revenue fell to $38.4 million from $52.9 million.

Oncology was the growth engine, at $387.1 million versus $287.8 million. Zepzelca rose 32% to $104.4 million, which the company tied to uptake of the atezolizumab combination in first-line maintenance extensive-stage small-cell lung cancer, partly offset by lower second-line use. Modeyso contributed $61.1 million, against $11.0 million in the year-earlier quarter, which preceded its August 2025 approval. About 725 patients have received it since launch. Rylaze/Enrylaze ($106.3 million vs $99.9 million) and Defitelio ($60.7 million vs $51.7 million) also grew, while Vyxeos declined to $34.0 million from $37.6 million.

Epidiolex/Epidyolex was the soft spot. Net sales fell 2% to $295.4 million from $302.6 million. The company said growth was hurt by lower U.S. gross-to-net deductions in 3Q25 and by lower inventory build in 3Q26 due to wholesaler buying patterns.

Ziihera: a small base and early launch signals

Ziihera sales were $20.6 million, up from $8.3 million. The FDA approved first-line HER2+ gastroesophageal adenocarcinoma (GEA) on August 25, 2026. The company said the first full month of launch showed a roughly 40% increase in average demand vials per selling day and a threefold increase in new ordering accounts, 80% of them community-based.

On evidence, Jazz presented final HERIZON-GEA-01 data at ESMO. It said Ziihera plus tislelizumab and chemotherapy showed an overall survival hazard ratio of 0.65, with nearly 40% of patients alive at three years and median OS of 27 months. The company also said NCCN guidelines now list Ziihera-based regimens, with or without Tevimbra, as a preferred first-line option. These are early indicators from a single month, not yet a sales trajectory.

Costs and margins

GAAP gross margin on total revenues improved to 91.1% from 88.6%. The company said cost of product sales fell mainly because the inventory fair value step-up was fully recognized in 2Q26, partly offset by higher royalties on Modeyso and Zepzelca. Non-GAAP gross margin moved the other way, to 91.5% from 92.6%, on those higher royalty expenses.

GAAP SG&A fell to $407.9 million (32.8% of revenue) from $530.6 million (47.1%). Non-GAAP SG&A was $328.0 million (26.4%) versus $460.1 million (40.9%). The company said the decline mainly reflects $152 million of litigation settlements in 3Q25, partly offset on a GAAP basis by $34 million of 3Q26 restructuring expense. R&D rose to $211.9 million GAAP ($188.9 million non-GAAP), reflecting pipeline and evidence-generation investment.

Tax is noisy. Jazz booked $24.5 million of GAAP tax expense versus a $242.4 million benefit a year ago, which included a $206 million benefit from recognizing deferred tax assets acquired with Chimerix.

Guidance and balance sheet

Full-year 2026 revenue guidance rose to $4,775-$4,850 million from $4,600-$4,750 million set on August 3. GAAP SG&A guidance increased to $1,544-$1,597 million to include restructuring costs, while GAAP R&D moved slightly to $819-$876 million. GAAP gross margin guidance held at 89%-90%; the non-GAAP range rose to 90.5%-91.5%. The effective tax rate ranges rose to 20%-30% GAAP and 19.5%-21.5% non-GAAP, reflecting the Actio IPR&D. Non-GAAP SG&A and R&D guidance were unchanged.

Cash, cash equivalents and investments were $2.9 billion at September 30, against $5.6 billion of long-term debt principal and $885 million of undrawn revolver capacity. Operating cash flow was $1.3 billion for nine months. In the quarter Jazz placed $1.25 billion of 1.875% exchangeable senior notes due 2032 and repurchased $225 million of shares, exhausting its July 2024 program. It extended its Term Loan B to May 2033 with a 50 basis point lower margin. In October the board authorized a new buyback of up to $500 million.

Catalysts and what to watch

Near-term markers include initial ABS-1230 patient data at a medical meeting in 4Q26. The drug is being tested in the Phase 1b/2a KYRON trial, which the company said is designed to be registrational for a U.S. NDA. The interim overall survival analysis of the Phase 3 ACTION trial for Modeyso is expected in 1H27, based on the current pace of event accrual. The PDUFA date for the oral cannabidiol capsule formulation of Epidiolex is April 16, 2027.

Also worth tracking are Ziihera's conversion of early demand into sales, the Epidiolex trend once wholesaler buying normalizes, and Zepzelca after the FDA removed the second-line indication on September 30.